<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-89967</identifier>
<setSpec>1134-8046</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Introduction: the scientific literature suggests that two in every three patients with chronic pain every so often suffer from transient exacerbations because of various causes, some of them predictable and some unexpected. In addition to the suffering they bring about, these episodes represent a relevant issue for patients as they trigger anxiety and add functional disability, which translates into greater difficulties in controlling baseline pain and lower quality of life. In 1990 the term &#147;breakthrough pain&#148; was coined in the United States to define transient cancer pain exacerbations under appropriate pain management with major opioids. In 2002, Sociedad Española de Oncología Médica (SEOM), Sociedad Española de Cuidados Paliativos (SECPAL), and Sociedad Española del Dolor (SED) defined a consensus document wherein the term &#147;dolor irruptivo&#148; (irruptive pain) was adopted to define sudden, transient (usually less than 20- 30 minutes), severe (VAS &gt; 7) pain breakouts on the background of stable, persistent pain that remains tolerable (VAS &lt; 5) under primarily major opioids. Overall, three etiologies are recognized for irruptive pain: incidental irruptive pain; idiopathic or spontaneous irruptive pain, and irruptive pain from end-of-dose medication failure. Objectives: the main goal of this work was to retrospectively study the effectiveness of sublingual fentanyl citrate in 180 patients treated for irruptive pain in Andalusian pain units during 1 month. Secondary goals included a description of the clinical indications and epidemiologic features of patients with irruptive pain under sublingual fentanyl citrate; understanding sublingual fentanyl citrate regimens for patients with irruptive pain; and a research of adverse events potentially associated with the use of sublingual fentanyl citrate in patients with irruptive pain. Material and methods: a retrospective, observational study of 180 patients, of whom 173 completed the study. Inclusion criteria (patients had to meet one of the following two) were: IP episodes with VAS &gt; 5 during the last 12-24 hours and/or undesired side effects arising from the current therapy for irruptive pain. Within the primary goal an analysis of the results for each VAS follow-up, the number of irruptive pain events, and pain relief onset was performed. Similarly, an analysis was also performed to compare these variables in the cancer pain group versus the non-cancer pain group, and in the idiopathic pain group versus the incidental pain group. Regarding secondary goals, age, gender, patient profile (adverse effects and irruptive pain episodes), active substance for baseline pain management, percentage of patients taking an additional 100 mcg dose of sublingual fentanyl, fentanyl dose per episode, mean fentanyl dose a day, and adverse effects were also analyzed...(AU)</dc:description>
<dc:creator>González, J. M</dc:creator>
<dc:creator>Rodríguez Matallana, M</dc:creator>
<dc:creator>Neira, F</dc:creator>
<dc:creator>Velázquez, I</dc:creator>
<dc:creator>Fernández, M</dc:creator>
<dc:creator>Cobo, R</dc:creator>
<dc:creator>Gallego, J</dc:creator>
<dc:creator>Rubio, A</dc:creator>
<dc:creator>Martínez, J</dc:creator>
<dc:creator>Torres, LM</dc:creator>
<dc:creator>Romero, J</dc:creator>
<dc:creator>Rodríguez, MJ</dc:creator>
<dc:creator>Ruiz, S</dc:creator>
<dc:creator>Ortega, J. L</dc:creator>
<dc:creator>Aldaya, C</dc:creator>
<dc:creator>Salmerón, J</dc:creator>
<dc:creator>Trinidad, JM</dc:creator>
<dc:creator>Contreras, D</dc:creator>
<dc:creator>Herrera, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: la literatura científica indica que dos de cada tres pacientes con dolor crónico sufren con cierta frecuencia exacerbaciones puntuales del mismo debido a diferentes causas, en ocasiones previsibles, y en otras inesperadas. Además del sufrimiento que conllevan, estos episodios constituyen un problema importante para el paciente pues generan ansiedad y añaden incapacidad funcional, lo cual se traduce en una mayor dificultad para controlar el dolor basal y una menor calidad de vida. En 1990 se acuñó en Estados Unidos el término &#147;breakthrough pain&#148;, para definir a las exacerbaciones transitorias de un dolor oncológico, que está bien controlado con la utilización de opioides mayores. En el año 2002, la Sociedad Española de Oncología Médica (SEOM), la Sociedad Española de Cuidados Paliativos (SECPAL) y la Sociedad Española del Dolor (SED), establecieron un documento de consenso en el que asumieron el término &#147;dolor irruptivo&#148;, para definir una exacerbación del dolor de forma súbita y transitoria, de gran intensidad (EVA &gt; 7) y de corta duración (usualmente inferior a 20-30 minutos), que aparece sobre la base de un dolor persistente estable, cuando este se encuentra reducido a un nivel tolerable (EVA &lt; 5) mediante el uso fundamental de opioides mayores...(AU)</dc:description>
<dc:source>Rev. Soc. Esp. Dolor;18(4): 207-218, jul.-ago. 2011. tab, ilus</dc:source>
<dc:identifier>ibc-89967</dc:identifier>
<dc:title xml:lang="es">Análisis de efectividad del citrato de fentanilo sublingual en pacientes con dolor irruptivo: estudio Sublime</dc:title>
<dc:subject>^d712^s22045</dc:subject>
<dc:subject>^d28599</dc:subject>
<dc:subject>^d^s22045</dc:subject>
<dc:subject>^d32099^s22049</dc:subject>
<dc:subject>^d32350^s22057</dc:subject>
<dc:subject>^d^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d10333^s22027</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28037^s22073</dc:subject>
<dc:subject>^d10333^s22057</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d10333^s22080</dc:subject>
<dc:subject>^d32099^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201108</dc:date>
</metadata>
</record>
</ibecs-document>
